Unlock instant, AI-driven research and patent intelligence for your innovation.
Application of oxyberberine in preparation of medicament for treating ulcerative colitis
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology for ulcerative colitis and berberine, applied in the field of biomedicine, can solve problems such as curative effect and safety limitations, achieve anti-arrhythmic efficacy, good application prospects, and improve the effect of general symptoms
Inactive Publication Date: 2019-09-13
GUANGZHOU UNIVERSITY OF CHINESE MEDICINE
View PDF0 Cites 5 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
Although some progress has been made in the research of the above drugs, these drugs have limitations in terms of efficacy and safety
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0033] The effect of embodiment 1 oxidized berberine on ulcerative colitis
[0034] 1 Experimental materials
[0035] 1.1 Experimental drugs
[0036] Berberinehydrochloride (BBR) was purchased from Chengdu Zhibiao Pure Biotechnology Co., Ltd.; oxidized berberine (OBB, self-made) (purity ≥ 98%); azathioprine (AZA) was purchased from Aspen Pharmacare Australia Pty Ltd. (Leonards, New South Wales, Australia).
[0037] 1.2 Experimental reagents
[0038] Dextransodiumsulfate (DSS, MW: 36000-50000) was purchased from MP Biomedicals, USA; the H&E staining kit was purchased from Wuhan Boster Biological Engineering Co., Ltd.; myeloperoxidase (MPO) kit was purchased from Nanjing Jiancheng Institute of Bioengineering; mouse ELISA kits: TNF-α, IL-6, IL-1β, IL-10, IL-17 and IFN-γ, purchased from Beijing Chenglin Biology; mouse IgA, IgM and IgG Elisa kits were purchased from Xinbosheng Biotechnology Co., Ltd. Antibodies JAM-A, Claudin-1, Occludin, ZO-1, ZO-2, β-actin and horseradish ...
Embodiment 2
[0088] Embodiment 2 treats the oxidized berberine medicament (tablet) of ulcerative colitis
[0089] Take 500g of oxidized berberine, add 480g of lactose and 754g of starch, mix evenly, use 7% starchslurry 350g as a binder, wet granulate, dry, add 16g of magnesiumstearate, mix evenly, and press to make each tablet contain oxidized berberine. 10,000 tablets of berberine 50mg, each with a net weight of 0.21g.
[0090] Orally, for the treatment of ulcerative colitis.
[0092] Embodiment 3 treats the oxidized berberine medicament (capsule) of ulcerative colitis
[0093] Take 500g of oxidized berberine, add 980g of lactose, 1254g of starch and mix evenly, use 7% starch slurry 350g as a binder, wet granulate, dry, add 16g of magnesiumstearate, mix evenly, fill to No. 1 capsule 10,000 capsules, each capsule contains 50mg of oxidized berberine, and the net weight of each capsule is 0.31g.
[0094] Orally, for the treatment of ulcerative colitis.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention discloses application of oxyberberine in preparation of a medicament for treating ulcerative colitis. The research of the invention finds that: the oxyberberine can safely and effectively resistulcerative colitis, and comprises the following effects: remarkably improving general symptoms of ulcerative colitis mice, improving pathological injury, reducing the level of colon tissue inflammatory cytokines and immunoglobulins in serum, and increasing expression of tight junction proteins (TJs) in colon tissues. The drug effect of the oxyberberine for preventing and treating the ulcerative colitis is equivalent to that of azathiopurine of a traditional first-line treatment drug, and is superior to that of berberine. In addition, the oxyberberine has high safety, and the daily application dosage of the oxyberberine is not strictly limited in terms of safety and can be adjusted according to clinical actual conditions during use, so that better curative effect is ensured. The invention provides a better new drug choice for clinically treating ulcerative colitis, and the oxyberberine has good application prospect for clinical treatment of ulcerative colitis.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More 
